US nicotine pouch fast-track scheme slowed by worries over youth, new users
The US FDA has slowed down the approval process for nicotine pouch products due to concerns over their potential risks to youth and new users. The delay has affected tobacco companies like Philip Morris International and British American Tobacco, which have pending applications for their products.
The FDA has halted the fast-track approval of nicotine pouch products in the US. The agency is concerned about the potential risks to youth and new users. Nicotine pouches are popular alternatives to smoking, with millions of users in the US. The FDA is weighing the benefits of these products against the risks, including addiction and harm to developing brains. Tobacco companies like Philip Morris International and British American Tobacco have pending applications for their products. The delay has impacted their stock prices, with PMI's shares falling over 7% on Wednesday.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.